Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03794076
PHASE1/PHASE2

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

Sponsor: Vishwajit Nimgaonkar, MD PhD

View on ClinicalTrials.gov

Summary

This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.

Official title: Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2019-04-01

Completion Date

2028-06

Last Updated

2026-03-19

Healthy Volunteers

No

Interventions

DRUG

Cromoglycate

Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray

DRUG

Placebo

Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)

Locations (1)

University of Pittsburgh

Pittsburgh, Pennsylvania, United States